MannKind Corporation to Participate in the Lytham Partners Fall 2022 Investor Conference

Rhea-AI Summary

MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company's webcast presentation will be available on September 28 at 9:00 am ET via its website. Additionally, management will hold virtual one-on-one meetings during the event. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, particularly utilizing advanced dry-powder formulations and inhalation devices.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

The Company’s webcast presentation will be available for viewing at 9:00am ET on Wednesday, September 28, 2022, on the Company's website at Events & Presentations or https://investors.mannkindcorp.com/events-and-presentations. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.

We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.

With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram.

Company Contact:
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com

 

FAQ

When is MannKind Corporation's webcast presentation at the Lytham Partners Fall 2022 Investor Conference?

MannKind Corporation's webcast presentation will take place on September 28, 2022, at 9:00 am ET.

Who is presenting at the Lytham Partners Fall 2022 Investor Conference for MNKD?

Michael Castagna, PharmD, the CEO of MannKind Corporation, will be presenting.

How can I access MannKind's presentation at the Lytham Partners Conference?

You can access the presentation through MannKind's website under Events & Presentations.

What type of products does MannKind Corporation focus on?

MannKind Corporation focuses on innovative therapeutic products for endocrine and orphan lung diseases.

Are there opportunities to meet with MannKind's management during the investor conference?

Yes, management will be participating in virtual one-on-one meetings during the conference.